

April 2020 updates to prior authorizations and post service claim edits

Security Health Plan (SHP) requires prior authorization (PA) and post service claim edits (PSCE) on certain medications in order to ensure coverage and payment for those services. A number of requirements have been added for 2020 as we work to make sure all care, services and treatments are medically necessary.

Magellan will implement additional PAs & PSCEs April 1, 2020, which include:

Specialty Drugs in the office-based and outpatient settings

- Beovu® (brolucizumab-dblI)
- Evenity® (romosozumab-aqqg)
- Infugem® (gemcitabine hydrochloride)
- Polivy® (polatuzumab vedotin-piiq)
- Udenyca® (pegfilgrastim-cbqv)
- Zirabev® (bevacizumab-bvzr)
- Asceniv® (immune globulin-slra)
- Nivestym® (filgrastim-aafi)

Magellan will implement additional PSCEs April 1, 2020, which include:

Specialty Drugs in the office-based and outpatient settings

- Aralast NP® (Alpha-1 Proteinase Inhibitor Human)
- Glassia® (Alpha-1 Proteinase Inhibitor Human)
- Prolastin-C® (Alpha-1 Proteinase Inhibitor Human)
- Zemaira® (Alpha-1 Proteinase Inhibitor Human)
- Faslodex® (fulvestrant)
- Bortezomib

Additional information:

- There is a delay in PA implementation for these two drugs that were slated for the Jan. 1, 2020, go-live date for PA and PSCE with Magellan
 - Kanjinti® (trastuzumab-anns)
 - Zilretta® (triamcinolone)

This is only the list of the new prior authorizations and post service claim edits required of members and providers to ensure payment for services. You can review the full list of medications that will require a prior authorization and/or post service claim edit on our website at www.securityhealth.org/providers/medical-pharmacy. If you have any questions, please contact Security Health Plan Provider Relations at 1-800-548-1224 (TTY: 711).